Literature DB >> 33539032

FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?

Irene S Yu1, Jonathan M Loree2.   

Abstract

This commentary focuses on the results of the study by Pietrantonio et al., which evaluated the clinical conundrum of triplet versus doublet chemotherapy in combination with targeted therapy for metastatic left-sided RAS/BRAF wild-type colorectal cancer and appears in this issue. Both FOLFOXIRI [fluorouracil, leucovorin, oxaliplatin, and irinotecan] plus bevacizumab and FOLFOX [fluorouracil, leucovorin, and oxaliplatin] plus panitumumab have shown impressive activity in this population; however, the two have not been directly compared. The article by Pietrantonio et al. presents a propensity score-adjusted analysis using information from five previous randomized trials and provides best available evidence comparing these regimens. This commentary will discuss their results and how their findings fit in current treatment paradigms.
© 2021 AlphaMed Press.

Entities:  

Year:  2021        PMID： 33539032      PMCID： PMC8018293          DOI： 10.1002/onco.13705

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  14 in total

Review 1.  The continuum of care: a paradigm for the management of metastatic colorectal cancer.

Authors:  Richard M Goldberg; Mace L Rothenberg; Eric Van Cutsem; Al B Benson; Charles D Blanke; Robert B Diasio; Axel Grothey; Heinz-Josef Lenz; Neal J Meropol; Ramesh K Ramanathan; Carlos H Roberto Becerra; Rita Wickham; Delma Armstrong; Carol Viele
Journal:  Oncologist       Date:  2007-01

2.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Axel Grothey; Rona Yaeger; Eric Van Cutsem; Jayesh Desai; Takayuki Yoshino; Harpreet Wasan; Fortunato Ciardiello; Fotios Loupakis; Yong Sang Hong; Neeltje Steeghs; Tormod K Guren; Hendrik-Tobias Arkenau; Pilar Garcia-Alfonso; Per Pfeiffer; Sergey Orlov; Sara Lonardi; Elena Elez; Tae-Won Kim; Jan H M Schellens; Christina Guo; Asha Krishnan; Jeroen Dekervel; Van Morris; Aitana Calvo Ferrandiz; L S Tarpgaard; Michael Braun; Ashwin Gollerkeri; Christopher Keir; Kati Maharry; Michael Pickard; Janna Christy-Bittel; Lisa Anderson; Victor Sandor; Josep Tabernero
Journal:  N Engl J Med       Date:  2019-09-30       Impact factor: 91.245

3.  Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

Authors:  Herbert I Hurwitz; Niall C Tebbutt; Fairooz Kabbinavar; Bruce J Giantonio; Zhong-Zhen Guan; Lada Mitchell; Daniel Waterkamp; Josep Tabernero
Journal:  Oncologist       Date:  2013-07-23

4.  Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis.

Authors:  Jenny E Chu; Benny Johnson; Laveniya Kugathasan; Van K Morris; Kanwal Raghav; Lucas Swanson; Howard J Lim; Daniel J Renouf; Sharlene Gill; Robert Wolber; Aly Karsan; Scott Kopetz; David F Schaeffer; Jonathan M Loree
Journal:  Clin Cancer Res       Date:  2020-06-22       Impact factor: 12.531

5.  FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.

Authors:  Filippo Pietrantonio; Giovanni Fucà; Daniele Rossini; Hans-Joachim Schmoll; Johanna C Bendell; Federica Morano; Carlotta Antoniotti; Salvatore Corallo; Beatrice Borelli; Alessandra Raimondi; Federica Marmorino; Monica Niger; Alessandra Boccaccino; Gianluca Masi; Sara Lonardi; Luca Boni; Filippo de Braud; Maria Di Bartolomeo; Alfredo Falcone; Chiara Cremolini
Journal:  Oncologist       Date:  2021-01-02

6.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.

Authors:  Barbara Melosky; Helen Anderson; Ronald L Burkes; Quincy Chu; Desiree Hao; Vincent Ho; Cheryl Ho; Wendy Lam; Christopher W Lee; Natasha B Leighl; Nevin Murray; Sophie Sun; Robert Winston; Janessa J Laskin
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

8.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Authors:  Chiara Cremolini; Fotios Loupakis; Carlotta Antoniotti; Cristiana Lupi; Elisa Sensi; Sara Lonardi; Silvia Mezi; Gianluca Tomasello; Monica Ronzoni; Alberto Zaniboni; Giuseppe Tonini; Chiara Carlomagno; Giacomo Allegrini; Silvana Chiara; Mauro D'Amico; Cristina Granetto; Marina Cazzaniga; Luca Boni; Gabriella Fontanini; Alfredo Falcone
Journal:  Lancet Oncol       Date:  2015-08-31       Impact factor: 41.316

9.  TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.

Authors:  Beatrice Borelli; Roberto Moretto; Sara Lonardi; Andrea Bonetti; Carlotta Antoniotti; Filippo Pietrantonio; Gianluca Masi; Valentina Burgio; Federica Marmorino; Lisa Salvatore; Daniele Rossini; Alberto Zaniboni; Gemma Zucchelli; Angelo Martignetti; Monica Di Battista; Nicoletta Pella; Alessandro Passardi; Alessandra Boccaccino; Francesco Leone; Camilla Colombo; Cristina Granetto; Francesca Vannini; Valentina Angela Marsico; Erika Martinelli; Lorenzo Antonuzzo; Stefano Vitello; Laura Delliponti; Luca Boni; Chiara Cremolini; Alfredo Falcone
Journal:  ESMO Open       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.